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Background: Point mutations and structural variations (SVs) in mitochondrial DNA (mtDNA) contribute to
many neurodegenerative diseases. Technical limitations and heteroplasmy, however, have impeded their
identification, preventing these changes from being examined in neurons in healthy and disease states.
Methods: We have developed a high-resolution technique—Mitochondrial DNA Structural Variation
Sequencing (MitoSV-seq)—that identifies all types of mtDNA SVs and single-nucleotide variations (SNVs) in
single neurons and novel variations that have been undetectable with conventional techniques.
Findings: Using MitoSV-seq, we discovered SVs/SNVs in dopaminergic neurons in the Ifnar1/murine model
of Parkinson disease. Further, MitoSV-seq was found to have broad applicability, delivering high-quality,
full-length mtDNA sequences in a species-independent manner from human PBMCs, haematological cancers,
and tumour cell lines, regardless of heteroplasmy. We characterised several common SVs in haematological
cancers (AML and MDS) that were linked to the same mtDNA region, MT-ND5, using only 10 cells, indicating
the power of MitoSV-seq in determining single-cancer-cell ontologies. Notably, the MT-ND5 hotspot, shared
between all examined cancers and Ifnar1/ dopaminergic neurons, suggests that its mutations have clinical
value as disease biomarkers.
Interpretation: MitoSV-seq identifies disease-relevant mtDNA mutations in single cells with high resolution,
rendering it a potential drug screening platform in neurodegenerative diseases and cancers.
Funding: The Lundbeck Foundation, Danish Council for Independent Research-Medicine, and European Union
Horizon 2020 Research and Innovation Programme.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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The mitochondrion is an energy-producing organelle that con-
tains its own genome [1]. Although the mitochondrial genome has
been believed to be inherited exclusively maternally, a recent study
has demonstrated biparental transmission of mtDNA in an autosomal
dominant-like pattern [2]. Mitochondrial diseases can arise from
defects in nuclear-encoded and mitochondrial-encoded genes [3].
mtDNA diseases have variable clinical features, because mtDNAdeficiency affects many tissues, and the involvement of mtDNA
genetic mutations has been debated in neurodegenerative disorders,
aging, and cancer due to their high energy consumption [3]. The
accumulation of mtDNA mutations impairs the electron transport
chain, triggers oxidative damage, and generates reactive oxygen spe-
cies (ROS)—specifically, HO radicals that form from H2O2 by Fenton
reaction—which can contribute to energy failure and lead to neurode-
generative diseases [4,5].
Neurodegenerative disorders, such as Parkinson disease (PD) and
Alzheimer disease (AD), are characterized by progressive nervous
system dysfunction, but the causal genetic basis of most age-related
neurodegenerative diseases is largely unknown. Approximately
510% of PD cases arise due to mutations in disease-related genes,
RESEARCH IN CONTEXT
Evidence before this study
Somatic mitochondrial DNA alterations have been linked to
neurodegeneration and are found in all types of cancer. How-
ever, due to heteroplasmy—the presence of several hundred
copies of the circular mitochondrial genome in a cell—it is diffi-
cult to identify and analyse disease-causing mutations in mito-
chondrial DNA. Further, there are no tools with which such
mutations can be detected with sufficient accuracy in single
cells, especially neurons.
Added value of this study
Our method, Mitochondrial DNA Structural Variation Sequenc-
ing (MitoSV-seq), is an advance in single-cell sequencing tech-
nology that has allowed us to detect novel mitochondrial DNA
mutations in purified dopaminergic neurons in a mouse model
of Parkinson disease easily while avoiding contamination. We
also confirmed its use in other cell types and cancers in human.
Moreover, we found a region of mitochondrial DNA that is
prone to mutations in several haematological cancers and
across species.
Implications of all the available evidence
MitoSV-seq is a powerful tool for discovering disease-associ-
ated mutations in mitochondrial DNA in single cells quickly
and specifically. MitoSV-seq has tremendous potential for
applications in the development of disease biomarkers and
drug screening platforms.
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genesis of PD [6]. In particular, somatic point mutations and larger
SVs in mtDNA in postmitotic neurons, especially in dopaminergic
(DA) neurons in the substantia nigra (SN), have been speculated to be
involved in PD [7-9], but the inferior sensitivity of mtDNA sequencing
techniques has made the identification of mtDNA genetic variations
unfeasible [10].
Somatic mitochondrial DNA alterations have been linked to neu-
rodegeneration and are found in all types of cancer [11]. Mitochon-
dria and their genomic instability could be important in several steps
of tumour development [12,13], because tumour cells switch from
oxidative phosphorylation to glycolysis to meet their energy
demands. In the initial stage of tumourigenesis, mtDNA is more likely
to be mutated as cancer cells begin adopting aerobic glycolysis. How-
ever, in late stages, they shift progressively to glycolytic metabolism,
which can promote the selection of cells in which the mutations ren-
der themmitochondrial function-independent [14]. Thus, by examin-
ing mtDNA-SVs and SNVs in single cells, the ontology of cancer cells
and their disease stages can be established.
Recurrent somatic alterations in mtDNA are found in 30% to 100%
of tumours, including breast cancer, colorectal carcinomas, and hae-
matological malignancies [12,13,15-19]. Mitochondria in cancerous
cells can contain a pool of somatic mtDNA alterations with a level of
heteroplasmy that is below current detection limits but has deleteri-
ous effects that alter mitochondrial function [20-23]. Heteroplasmy is
the presence of several hundred copies of the circular mitochondrial
genome in a cell. Mutations can arise in a small subset of mtDNAmol-
ecules, resulting in a heterogeneous pool of mtDNA [24], which nev-
ertheless could have a profound impact. In lung cancer, the rate of
mutant heteroplasmy ranges between 0.31% and 97.04% [25]. This
aspect becomes a significant issue when studying postmitotic cells,such as neurons, that might have high heteroplasmy that comprises
many mutations that are below the 0.5% threshold, because they are
not dividing.
The detection of rare heteroplasmic variations in whole mtDNA
requires extremely accurate tools to distinguish between a substan-
tial signal and background noise. Previous studies on mtDNA have
performed whole-cell sequencing, which typically includes mtDNA,
or have applied a combination of long-range polymerase chain reac-
tion (PCR), gel purification, and Sanger sequencing, resulting in the
omission of low-frequency heteroplasmic mtDNA deletions [9,26-
31]. Deletions are the most common SVs in mtDNA, but some reports
indicate the presence of inversions in mtDNA and their correlation
with aging and mtDNA instability [32-35]. Further, most mtDNA
deletions reside in the major arc, a region that lies between the ori-
gins of replication of the heavy and light strands. The major arc is
especially prone to deletions due to its high load of short repeats,
causing errors during mtDNA replication or repair [36]. Based on this
leading theory, most studies have concentrated on sequencing the
major arc rather than the entire mtDNA genome [37,38], necessitat-
ing sensitive, whole-mtDNA amplification and sequencing to increase
our understanding of mitochondrial genome mutations in relation to
diseases. Rolling circle amplification (RCA) is a useful tool for over-
coming the difficulty of amplifying circular mtDNA. RCA favours
amplification of circular templates (such as circular mtDNA),
although linear DNA (genomic DNA and linear mtDNA) can also be
amplified with RCA to a lesser extent [39]. RCA was first reported to
amplify vector DNA, such as M13, and plasmid DNA from single colo-
nies and plaques [40].
One method of circumventing the technical limitations that are
imposed by mtDNA heteroplasmy is single-cell analysis. The past sev-
eral years have witnessed rapid development of technologies that
analyse the genome and transcriptome of single cells in detail
[41,42]. Recent evidence from studies of single cells has shown that
each cell type has a distinct lineage and function, which determines
how they respond to each other and the environment—which has
particular relevance in cancer [43]. Cancer scDNAseq (single-cell
DNA sequencing) is especially useful for examining the depth of
genomic complexity and composite mutations, whereas conventional
bulk sequencing is unable to resolve the patterns by which these
mutations co-occur in single cells of a tumour [44]. Moreover, ampli-
fication of a single-cell genome—also known as a single amplified
genome (SAG)—followed by ultra-deep sequencing, provides greater
coverage depth of all genomic variations [45]. The evolutionary inte-
gration of nuclear mitochondrial DNA segment (NUMT) pseudogenes
in the nuclear genome must be considered in mtDNA deep sequenc-
ing [46], because they can affect the PCR amplification and read align-
ment of mtDNA, reducing the coverage of sequencing.
In this study, we describe a method that significantly supports
whole-mtDNA sequencing of single cells using sequence-agonist
random hexamers (RHs) for amplifying circular mtDNA. We dem-
onstrate that this application has the capacity to detect somatic
mtDNA SVs and SNVs in single DA neurons from the murine
brain. We have shown that mice that lack Ifnar1 (Ifnar1/)
develop a PD-like pathology that recapitulates most aspects of
the disease in humans, comprising protein aggregation in Lewy
body (LB)-like structures, progressive neurodegeneration, and
neurological manifestations of PD, including cognitive impair-
ments [47]. In the present study, we used this model as a source
of brain DA neurons, giving us access to the affected neurons at
an earlier stage of the disease. To perform mtDNA sequencing in
a particular type of neurons—in this case, DA neurons—they must
be separated from other neurons and other cell types, such as
glial cells. The preferred techniques for isolating single neurons
have been magnetic cell separation (MACS) [48] and laser capture
microdissection (LCM) [9,49], both of which can suffer from non-
specific contamination by other cell types [50].
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rons were isolated from the SN by fluorescence activated cell sorting
(FACS). Phi29 DNA polymerase was used to perform bulk amplifica-
tion of mtDNA by RCA [30,51,52] (generation of periodic DNA nano-
templates), after which ultra-deep sequencing was applied to detect
SNVs and all types of SVs with deep coverage. The RCA, library prepa-
ration, and data processing steps included a positive control (PC)—
mtDNA that carried a 4.3-kb deletion—allowing us to benchmark and
detect known and novel mtDNA variations that are associated with
PD pathology in this model that were not identified using conven-
tional techniques. We successfully applied and verified our new
MitoSV-seq method and characterised several mutations and varia-
tions due to mtDNA instability in various human cancers: breast can-
cer, colon cancer, and 2 primary cancers of myeloid lineage—acute
myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). The
higher resolution of mtDNA variations that are obtained using
MitoSV-seq at the single-cell level demonstrates the power of our
technique for single-cell analysis.
2. Materials and methods
2.1. Animals
Ifnar1/ mice [53] were backcrossed 20 generations to C57BL/6J
mice (IMSR Cat# JAX:000664, RRID:IMSR_JAX:000664) to generate the
Ifnar/ mice that were used in this study [47]. The wild-type animals
were Ifnar+/+ littermate mice. Mice were housed in standard facilities.
Sex- and weight-matched mice were used in the experiments, which
were performed in accordance with the animal use and ethical com-
mittee guidelines in Denmark and approved by our institutional review
boards (ethical permission #201315293400807). Mice were used
in triplicate.
2.2. Human samples
Fresh blood samples were obtained from 4 healthy donors (aged
26-46 years, 2 males and 2 females). PBMCs were isolated from fresh
blood or buffy coats using the SepMateTM PBMC Isolation kit (85450;
Stemcell Technologies). Fresh buffy coats were provided from 3
patients with AML (aged 53-78 years, males) and 3 patients with
MDS (aged 60-86 years, females) with multilineage dysplasia, who
provided informed consent regarding the collection and use of this
material.
Studies of the human samples were approved by the Danish Data
Protection Agency (J.nr. 2012-58-0004) and the National Committee
on Health Research Ethics (Project ID CVK-1705391).
2.3. Cell culture
Cortical neuron cultures: Primary cortical neuron (CN) cultures
were prepared by dissecting the cortex from 1-day-old Ifnar1 / and
Ifnar1+/+ mouse pups and cultured as described [54] for 6 days and
21 days. To obtain pure CNs, cultures were treated with 10 mM FUDR
(fluorodeoxyuridine) after 24 hours in culture; then, the culture
media was removed and replaced with normal media.
PBMC cultures: The basal culture media comprised RPMI-1640
medium with 1% (v/v) GlutaMAX-I, 1% (v/v) non-essential amino
acids, 1 mM sodium pyruvate, 50 mM b-mercaptoethanol, 50 U/ml
penicillin, 50 mg/ml streptomycin, 1% (v/v) kanamycin, and 5% (v/v)
human serum. PBMCs were cultured in a humidified chamber at 37 °
C, 5% CO2.
Cancer cell line cultures: The breast cancer cell lines MCF10A
(ATCC CRL-10317TM, RRID:CVCL_0598) and MCF7 (ATCC HTB-
22TM, RRID:CVCL_0031) and colon cancer cell lines SW480 (ATCC
CCL-228TM, RRID:CVCL_0546) and SW620 (ATCC CCL-227TM, RRID:
CVCL_0547) were cultured in Dulbecco Modified Eagle’s medium(DMEM) with Ham’s F12 nutrient supplement and 10% foetal
bovine serum (FBS). Cells were cultured in a humidified chamber
at 37 °C, 5% CO2.
Induction of mild oxidative stress: Cell lines and PBMCs from
healthy donors were treated in triplicate with 100 mM H2O2 for 24 h
and washed 3 times with PBS. The cells were then processed similarly
as untreated cells for single-cell isolation by cell sorting.2.4. Single-cell isolation by cell sorting
Dopaminergic neurons: We performed flow cytometry per Guez-
Barber et al. [57], with some modifications, to purify single neurons
from the SN—ie, DA neurons from dissected brain stems (including
the midbrain, pons, and medulla oblongata) from mice. Each BS was
placed in a microfuge tube with 1 ml of Low-Fluorescence Hibernate
A (HA-LF; Brain Bits) on ice, and the cells were dissociated according
to the protocol [55]. Next, 1 ml of Accutase (A1110501; Thermo Sci-
entificTM) was added for 15 min at 4 °C to dissociate the cells. Large
cell clusters and debris were removed from the cell suspension by
serial filtration through 100-mm and 40-mm cell strainers (Falcon
352360 and Falcon 352340; BD Bioscience).
Using Percoll (P1644; Sigma), 3-step density gradient centrifuga-
tion (high-density solution: 3426 ml Hibernate A + 824.5 ml
Percoll + 97.8 ml 1 M NaCl; medium-density solution: 3600 ml Hiber-
nate A + 650.5 ml Percoll + 76.5 ml 1 M NaCl; low-density solution:
3770 ml Hibernate A + 480.3 ml Percoll + 59.5 ml 1 M NaCl) was then
performed to remove small cellular debris [55]. One millilitre of each
solution (bottom: high-density; middle: medium-density; top: low-
density) was layered carefully in a 15-ml Falcon tube. The filtered cell
suspension (from the previous step) was applied to the top of this
gradient and centrifuged at 430£ g for 3 min at 4 °C. The cloudy top
layer (»2 ml), containing cell debris, was discarded. The cells in the
remaining layers were centrifuged at 550£ g for 5 min at 4 °C. Cell
pellets were resuspended in 1 ml of Hibernate A and divided into
microfuge tubes for immunolabelling. Cells were fixed in 50% ethanol
on ice for 15 min with occasional inversion, pelleted by centrifuga-
tion at 600£ g for 2 min, and resuspended in phosphate-buffered
saline (PBS). Dopaminergic neurons were co-labelled with antibodies
against NeuN (MAB377; Millipore, RRID:AB_2298772) and tyrosine
hydroxylase (TH; AB1542; Millipore, RRID:AB_90755), diluted 1:100
in PBS with 1% bovine serum albumin (BSA; A3608, Sigma).
During the incubation, DA neuronal cells were rotated for 30 min
at 4 °C. Next, the neurons were washed once by adding 800 ml PBS to
each tube and centrifuged at 950£ g for 3 min before being resus-
pended in PBS. The DA neurons were then incubated with fluorescent
labels and rotated for 15 min at 4 °C. TH and NeuN double-positive
cells (Fig. 3c) were incubated with Alexa Fluor 488-labelled anti-rab-
bit (Molecular Probes Cat# A-11070, RRID:AB_142134) and Alexa
Fluor 647-labelled anti-mouse (Molecular Probes Cat# A-21236,
RRID:AB_141725), diluted 1:1000 in PBS with 1% BSA. The cells were
washed again with 800 ml PBS and 1% BSA, centrifuged at 950£ g for
3 min, and resuspended in 1 mL PBS with 1% BSA on ice for the next
step.
The cells were sorted on a BD FACSAria II (BD Biosciences). A small
portion of fixed cells was incubated without antibodies to gate the
cells, and another portion was labelled only with secondary antibod-
ies to set the maximum threshold for nonspecific binding. Then, the
test samples that were labelled with primary antibodies and fluores-
cent labels were scanned and sorted at 4 °C. Single DA neurons were
sorted into 96-well PCR plates with 2 ml of mild lysis buffer (freshly
prepared 0.2% Triton X-100, 93443; Sigma), to be used directly in the
DNA amplification step. The plates were kept on ice or in IsoFreeze
PCR racks during the sort and stored at 80 °C for longer periods.
Myeloid cell isolation: Single myeloid cells were sorted using
CD11b (ab8878; Abcam, RRID:AB_306831) into 96-well PCR plates
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Eppendorf tubes (0030125150; Eppendorf) for bulk experiments.
Single cancer cell isolation: Cancer cells were stained with LIVE/
DEAD Fixable Violet (L34955; Invitrogen), and single living cells were
sorted into 96-well PCR plates.
2.5. Real-time quantitative PCR
After the purification of DA neuronal cells was confirmed, single
cells were treated with DNase. RNA from samples was reverse-tran-
scribed directly into cDNA using the QuantiTect Reverse Transcrip-
tion kit (205310; Hilden) according to the manufacturer’s
instructions. cDNA was analysed by real-time qPCR with primers that
were designed for TH and two nuclear housekeeping genes (Supple-
mentary Table 22), with each sample repeated in technical triplicate.
qPCR was performed using Maxima SYBR Green/ROX qPCR Master
Mix (K0222; Thermo ScientificTM).
2.6. MitoSV-seq protocol
2.6.1. Generation of a deleted mtDNA as PC for MitoSV-seq
We generated a 4.3-kb deletion as PC for SV from N2a mt-DNA as
follows:
a Mitochondrial fractionation from N2a cells and mtDNA
precipitation
N2a cells were scraped into 1X PBS (70011-036, Life Technologies)
and pelleted at 300 g for 3 min. The pellet was resuspended in mito-
chondrial isolation buffer, containing 5 mM HEPES (H3375-100G,
Sigma-Aldrich), 210 mM mannitol (63560, Fluka), 70 mM sucrose
(84100, Fluka), 0.2 mM EGTA (E3889-100G, Sigma-Aldrich), and
3 mM MgCl2 (M8266-100G, Sigma-Aldrich). Phosphatase inhibitor
cocktail (1:500) (P5726-5ML, Sigma-Aldrich) and protease inhibitor
cocktail (P8340, Sigma) were also added to the buffer. The cells were
lysed in mitochondrial isolation buffer by passing them through a
27G needle (302200, BD Microlance) 10 times, incubating them on
ice for 20 min, and passing them through the 27G needle another
10 times. The cells were centrifuged at 3000 rpm for 5 min, and the
supernatant was harvested and centrifuged again to clear it of poten-
tial nuclear contamination.
The supernatant was then centrifuged at 10,000 g for 10 min to
pellet the mitochondrial fraction. The supernatant, containing the
cytoplasmic fraction, was harvested and centrifuged again to elimi-
nate any mitochondrial contamination. The 2 mitochondrial pellets
were resuspended in mitochondrial isolation buffer, pooled, and cen-
trifuged at 10,000 g for 10 min and resuspended in RIPA (89900,
Thermo ScientificTM) to form the mitochondrial fraction. All centrifu-
gation steps were performed at 4 °C.
To precipitate the mtDNA from fractionated mitochondria, one-
tenth of the sample volume of proteinase K (1017738, QIAGEN) was
added and incubated at 56 °C for 10 min. One-tenth of the sample
volume of sodium acetate (TA942068, Merck) was added after the
incubation, followed by the addition of 2.5 times the sample volume
of absolute ethanol (1680766, CCS Healthcare). After being mixed
thoroughly, the samples were left at -20°C overnight and then centri-
fuged at full speed for 20 min at 4 °C. The DNA pellets were washed
with 70% ethanol (1680766, CCS Healthcare) and centrifuged at full
speed for 15 mins at 4 °C. The pellets were left to dry before being
dissolved in nuclease-free water.
b Introduction of 4.3-kb deletion in mouse mtDNA
A restriction map of mouse mtDNA was predicted using Gene
Runner (v6.5.51) to identify restriction enzymes with two cleavage
sites in mtDNA. NheI (R0131S, BioLabs) was used to digest themtDNA at 5930 bp and 10,395 bp, yielding two mtDNA fragments of
4345 bp and 11,950 bp. The digestion was performed at 37 °C for
3 hours.
The 11,950-bp fragment was purified from an agarose gel using
the GenepHlowTM Gel/PCR Kit (DFH100, Geneaid) (Fig. 3a-b) and
ligated using T4 DNA Ligase (EL0014, Thermo ScientificTM) for 1 hour
at room temperature before enzyme inactivation. The deletion in the
PC was confirmed by PCR (Supplementary Table 1).
2.6.2. mtDNA amplification by conventional methods
Total DNA from CNs and four types of malignant cells was purified
using the DNeasy Blood & Tissue Kits (69504, QIAGEN). Circular
mtDNA was amplified using two pairs of site-specific primers (MTL
primers) that were designed for human mtDNA (Supplementary
Table 1) and KOD Hot Start Master Mix (71842, Merck) according to
the manufacturer’s protocol. Amplified PCR fragments were purified
from agarose gels and processed for sequencing. The quantity and
size distribution of the mitochondrial amplicons (MTLF1 +MTLR1
and MTLF2 +MTLR2) were determined using Agilent DNA 12000
chips (5067-1508; Agilent Technologies) on an Agilent Technologies
2100 Bioanalyzer (G2939BA: Agilent Technologies).
2.6.3. MitoSV-seq mtDNA amplification
In MitoSV-seq, RCA of the circular mtDNA was performed using
Phi29 DNA Polymerase (Templiphi; GE Healthcare 25-6400-10). Two
microlitres of the cell lysate from 20 single DA neurons (10 individual
Ifnar1+/+ and Ifnar1/ cells each), 10 single myeloid cells from each
patient with AML and MDS and healthy donors, and 10 single cells
from each cell line (SW480, SW620, MCF10A, and MCF7) were used
as the template to be amplified with Phi29 DNA polymerase and RHs
according to the manufacturer’s protocol. For bulk amplification, the
entire genome was isolated using the DNeasy Blood & Tissue Kits
(69506; QIAGEN), and 2 ul (10 ng) was used for RCA.
Amplification was performed for 2 hours at 30 °C; longer amplifi-
cation times favoured genomic DNA amplification over mtDNA. The
PCR products were loaded onto an agarose gel (A9539; Sigma) to
assess the amplification of concatemers. TempliPhi-amplified DNA
was quantified by PicoGreen dsDNA quantitation assay (P7581;
Invitrogen). To confirm the RCA of the mtDNA and to increase the
efficiency of the library preparation for NGS, concatemers were
digested using XhoI (FD0694; Thermo ScientificTM), which has only
one restriction site in mouse mtDNA, into linear 16.3-kb fragments
(Fig. 3e). The resulting concatemers were processed directly for
sequencing.
To verify the propensity for circular DNA to be amplified, RCA was
performed as described above using purified mtDNA (circular) and
XhoI-linearized mtDNA, followed by purification (GenePhlow,
Geneaid).
2.6.4. Next-generation sequencing (NGS) and data processing
The digested concatemers from RCA and amplicons from the site-
specific PCR were processed for library preparation using the Nextera
XT DNA Library Preparation Kit (FC-131-1096, San Diego) according
to the manufacturer’s instructions. AMPPure XP beads were used to
purify the DNA library and provide a size selection step to remove
short library fragments. Bioanalyzer-based normalization was con-
ducted using the Agilent High-Sensitivity DNA kit (5067-4626, Agi-
lent Technologies) to determine the molarities of the libraries. The
libraries were pooled at equimolar amounts and run at 1.4 picomolar
(spiked with 1.4 picomolar PhiX) in paired-end 300-cycle high-mode
on an Illumina NextSeq 500 (Illumina Inc.), which produced
»400 million reads.
FASTQ files were transferred automatically to BaseSpace and qual-
ity-trimmed using Trimmomatic v0.36 [56], and adaptors were
removed using cutadapt v1.16. Reads were aligned using Bowtie2
[57] with default parameters against the mouse mtDNA reference
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NC_012920.1. Considering that mtDNA has a circular genome, align-
ment tools use a linear form as the reference to align sequence reads.
As a result, the reads that cover the artificial breakpoint in the circular
genome are not aligned properly and are discarded. We used two
frames of the mtDNA—one with a breakpoint in the replication con-
trol region to “start” at position 1 and “end” at position 16,299 for
mouse (16,569 for human) and a shifted mtDNA sequence with a
breakpoint in the internal region of the genome at position 3710.
Thus, the “shifted” reference sequence begins at original position
3710 and ends at original position 3709. Two frames were also used
for the human mtDNA sequence.
Mpileup was used to call SNVs with BAM files (SAM tools v0.1.19).
Variant calling was performed using VarScan2 (version 2.3.6) using
default parameters for SNVs and INDELs. VarScan Somatic was used
to compare the variations between wild-type cells (as germlines) and
knockout cells (as tumours). To maximize the specificity, reads were
not considered if their mapping quality was below 30 and if their
average per-base sequencing quality fell below 30. Pindel v0.2.5 [58]
was used to detect breakpoints of large structural variations, includ-
ing deletions, insertions, duplications, and inversions. Detected SVs
were discarded if fewer than 20 unique reads with an upstream
anchor and fewer than 20 unique reads with downstream anchors
spanned the variant area to maximize specificity by setting stricter
filtering criteria. Heteroplasmy% was calculated by dividing the total
number of mutations at a certain nucleotide position by the total
number of genomes that was represented at the position, multiplied
by 100.Fig. 1. Overview of MitoSV-seq method. Samples were collected from mouse brain, cancer
markers. PC preparation is optional, and although it is not necessary, it is highly recommen
molecular-weight concatemers were digested using XhoI. Tagmentation and indexing were p
run for paired-end 300-cycle high-mode sequencing on a NextSeq 500. NGS data were an
Neuro-2a; mtDNA, mitochondrial DNA; PC, positive control; RCA, rolling circle amplification;To analyse contamination by NUMTs, trimming and alignment
were performed using BWA (as described above), but instead of being
aligned to mouse mtDNA, it was mapped to mm10 or the entire
mouse genome, and reads that were lost due to NUMTs were quanti-
fied.
3. Results
3.1. Overview of MitoSV-seq method
To examine the function and association of mtDNA mutations in
human disorders, a sensitive method is required to scan all parts of
mtDNA and characterise all types of mtDNA mutations that confer
their selective advantages in progressive human diseases. To this
end, we developed the MitoSV-seq method to detail all types of
mtDNA genetic damage with various frequencies from a broad range
of cell types in a species-independent manner. MitoSV-seq generates
a clear pattern of mtDNA alterations that might affect mitochondrial
function in relation to neurodegeneration and cancers.
The MitoSV-seq workflow typically consists of 3 steps: (i) prepa-
ration of single cells, (ii) preparation of a positive control (PC), and
(iii) RCA and ultra-deep sequencing (Fig. 1). For the first step, single
cells can be obtained from solid tissues, such as brain (in this study,
brain stem but equally applicable to other parts of the brain); fluids,
including peripheral blood; and cell cultures. Single cells are sorted
using cell specific markers directly in lysis buffer. A PC for SV was
established by engineering a 4.3-kb deletion in the mtDNA to be used
as a premise for the experiment. RCA is performed on the PC and cellcell lines, and human buffy coats. Single cells were isolated by FACS using cell-specific
ded for mtDNA sequencing. PCs and single-cell lysates were amplified by RCA. High-
erformed using the Nextera XT DNA Library Preparation Kit. Libraries were pooled and
alysed using standard DNA-seq methods. Pindel [58] was applied for SV calling. N2a,
RHs, random hexamers; dNTP, deoxyribonucleotide triphosphate; DA, dopaminergic.
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Phi29 DNA polymerase to produce high-molecular-weight conca-
temers. To increase the efficiency of the library preparation step, the
concatemers were digested to 16.3-kb mtDNA fragments.
For the alignment and data analysis, we used two frames of
mtDNA to maintain coverage around the artificial breakpoint in the
circular genome. The average sequencing depth across the genome
was 30 § 2.30 for single cells. To circumvent the contamination of
NUMTs in our analytical pipeline [59], we aligned the sequencing
reads to the mtDNA genome rather than the entire genome (mm10
and hg19), preventing the loss of reads due to alignment to NUMTs.
The analysis included visualisation of SVs and SNVs using Circos
plots—the recommended schematic representation for mtDNA-SVs—
which can be created for all types of SVs and SNVs using Circlize
package 0.4.7. The script for autogenerating circos plots for mtDNA-
SVs and SNVs is provided as part of this study. The lists of SVs and
SNVs must be prepared in standardised browser extensible data
(BED) format.
3.2. Advantage of MitoSV-seq over existing approaches
There are many commercial protocols for sequencing mtDNA that
use Sanger sequencing or NGS from various suppliers that support
the identification of mtDNA mutations and structural variations.
These approaches are inadequately robust to amplify and sequence
all types of SVs and SNVs in mtDNA. Some of them are insufficiently
sensitive to detect minor heteroplasmic variations, although theseFig. 2. Step-by-step schematic between MitoSV-seq and conventional methods. Conventi
or single DA neurons isolated by MACS or LCM, followed by PCR amplification of mtDNA usin
ments are usually purified from agarose gels and processed for NGS library preparation and
from a heterogeneous pool of cells using cell-specific markers. Single cells are sorted and us
using RHs and phi29 DNA polymerase in a rolling circle manner. Addition of our custom PC
molecular-weight concatemers are digested and used for NGS library preparation and ultra-
PCR; polymerase chain reaction; FACS; fluorescence-activated cell sorting; RHs, random hexalow-frequency variations can still affect mitochondrial function in
regulating synaptic transmission, brain function, and cognition in
aging [60]. Similarly, certain mtDNA mutations, even those with a
low frequency, could confer a growth advantage to a small popula-
tion of treatment-resistant cancer cells, which in turn could potenti-
ate recurrence or generate metastatic potential. Despite attempts to
sequence mtDNA in single cells, most studies have merely analysed a
small region of mtDNA [primarily the D-loop, the noncoding dis-
placement (D) loop] [61,62], which might underestimate the impor-
tance of all mitochondrially encoded genes in human disorders.
The MitoSV-seq method is easy to set up for many species (tested
in mouse and human) in a high-throughput manner due to the appli-
cation of RHs rather than site-specific primers, which can hybridise
to DNA from bulk cells and that from a single cell. Bench implementa-
tion confirmed the use of MitoSV-seq in the identification of all types
of mtDNA genetic variations in various disease-specific cell types.
MitoSV-seq also assesses mtDNA damage at the single-cell level with
better sensitivity and output compared with bulk samples due to the
greater sequencing depth that can be obtained with the mtDNA cop-
ies of a single cell. Bulk sequencing reduces the depth of sequencing
for each copy of mtDNA, diluting the detected variations.
Fig. 2 presents a step-by-step comparison of mtDNA sequencing
between conventional methods and our newly developed high-reso-
lution MitoSV-seq technique. Conventional methods have focused
primarily on brain homogenates or bulk cortical neuron (CN) cultures
to identify mtDNA variations in neurodegenerative conditions.
Because DA neurons are more sensitive to mitochondrial deficiencyonal methods have focused primarily on brain homogenate, bulk cortical neurons (CNs),
g site-specific primers designed mainly for the D-loop or major arc. Amplified PCR frag-
sequencing. MitoSV-seq benefits from FACS in characterising and isolating single cells
ed directly for the amplification step. Concatemers from circular mtDNA are generated
allows to us to first set up the analytical pipeline to find a known PC deletion. High-
deep sequencing. MACS, magnetic cell separation; LCM, laser capture microdissection;
mers; RCA, rolling circle amplification; PC, positive control.
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types in the brain, using brain homogenates might dilute the number
of variations and their heteroplasmy.
Several studies have attempted to determine the distribution of
mtDNA variations in single DA neurons. The most commonly used
and recommended techniques for isolating single neurons have been
magnetic cell separation (MACS) [48] and laser capture microdissec-
tion (LCM) [9,49], which have a higher probability of nonspecific con-
tamination by other cell types. Nonspecific contamination during
MACS can arise from the adsorption of background cells to the cap-
ture device. Further, immunomagnetic techniques can only separate
cells into positive and negative populations, which is not useful for
double or multiple selection of cells using specific antibodies [63].
Also, the separation of a minute population of cells or single cells
from a heterogeneous population using LCM can be inaccurate and is
more prone to contamination from neighbouring cells, compounded
by the limitations of being combined with multiple antibody stains.
The sample preparation for LCM can affect the integrity of mtDNA,
and the quality of microdissected cells might fall short of the quality
that is required for further analysis [50].
In this study, we confirmed that FACS is an efficient and feasible
technique for characterising and sorting various cell types in a het-
erogeneous cell population, based on the exclusion of duplets, cell
size, granularity, and combination of specific cell markers that are
stained with fluorescently labelled antibodies. Also, FACS ensures the
selection of live cells on live/dead cell gating. To prevent the degrada-
tion of mtDNA, times for performing the steps should be considered.
For isolating single DA neurons, the time from dissection of the brain
to fixation should be under 30 min. Buffy coats and resuspended cell
cultures should be kept on ice before fixation. Another issue regard-
ing the conventional methods is the amplification of mtDNA by
primer-specific PCR and gel purification. The combination of these
techniques can lead to the loss of infrequent SVs, which cannot be
observed on an agarose gel for excision and purification. MitoSV-seq
applies RCA using RHs, with a greater tendency to amplify circular
DNA over linearized DNA (Supp. Fig. 1), promoting the amplification
of circular mtDNA over linearized DNA. Further, RCA amplifies DNA
from various sections, which will not be affected by any SV or point
mutation in the mtDNA.
3.3. Evaluation of MitoSV-seq in single dopaminergic neurons from a PD
model: Ifnar1/mice
The efficacy of the method was evaluated in Ifnar1/ mice, a
mouse model of PD. Neurons in this model experience oxidative
phosphorylation damage to mtDNA, which induces neuronal accu-
mulation of senescent or damaged mitochondria [47]. Initially, we
struggled to determine the genetic basis of the mitochondrial damage
in Ifnar1 / mice using conventional techniques, because only two
SNVs and no SVs were seen in days in vitro (DIV)=6 CN cultures, ver-
sus 27 SNVs and no SVs in DIV=21 CN cultures (Fig. 3). To overcome
this deficiency, we designed the MitoSV-seq method and compared
its efficacy with conventional techniques.
One advantage of using animal models to study neurodegener-
ation is that we can focus on earlier stages of the disease, when
dopaminergic neurons in the SN are still alive. We chose 6-week-
old mice, the time at which brain development has completed
[64] but before most PD pathological features, such as LB and
motor dysfunction, are observed [47]. Based on reports that have
challenged the ability of NGS to find deletions and other struc-
tural variations in mtDNA [9,26-31], we designed an internal PC
for MitoSV-seq by introducing a 4.3-kb deletion from 5930 bp to
10,395 bp into mouse mtDNA to benchmark our method (Fig. 3a-
b). The addition of this PC allowed us to establish our analytical
pipeline to detect a known PC deletion, after which we applied
our method to other samples.To purify single DA neurons from the SN, we performed flow
cytometry to select double-positive neurons for NeuN (neuronal
nuclei) and tyrosine hydroxylase (TH) in Ifnar1+/+ and Ifnar1/ mice
(Fig. 3c). We validated the purity of this neuronal sorting by qPCR,
which demonstrated the expression of TH in isolated single cells
(Fig. 3d). The mtDNA that was released from each single cell and the
PC was amplified with Phi29 DNA polymerase and RHs. Concatemers
were digested to create linear mtDNA fragments and increase the
efficiency of the library preparation for NGS (Fig. 3e). Ultra-deep
sequencing (UDS) of mtDNA yielded »1 Gbp per individual neuron
and detected 127 SVs and 143 SNVs in 7 of 10 neurons (70%) in
Ifnar1/mice (Fig. 3f) compared with WT samples.
The identified SVs were distributed among 4 types with various
percentages of heteroplasmy: 41 deletions (DELs), 24 inversions
(INVs), 38 insertions (INSs), and 24 tandem duplications (TDs)
(Fig. 3g). One INV and 1 TD reached 100% and 67%, respectively—ie,
greater than the 50% heteroplasmy that had been suggested as the
threshold for heteroplasmy that was necessary for pathogenicity. The
SVs resided in mitochondrial tRNA genes, rRNA-encoding genes (mt-
Rnr1), and the protein-encoding genes mt-Nd2, mt-Co1, mt-Atp6, mt-
Co3, mt-Nd4, mt-Nd5, and mt-Nd6 (Fig. 3h; Supplementary Table 1).
Mutations in mt-ND4, encoding mitochondrial NADH dehydrogenase
4, have been associated with Leber optic atrophy [65] and MELAS
syndrome [66]. Mutations in mt-ND5, the gene for mitochondrial
NADH dehydrogenase 5, have been reported in Parkinson disease
and LEIGH syndrome [67]. The genes that encode mitochondrial
tRNAs are highly susceptible to point mutations and deletions, which
are a primary cause of mitochondrial dysfunction and are linked to a
wide range of pathologies, including cardiomyopathy, pigmentary
retinopathy, sensorineural deafness, cataract, cerebellar ataxia, and
diabetes mellitus [68].
MitoSV-seq identified SNVs in Ifnar1/ neurons at higher resolu-
tion, which were distributed throughout the mtDNA (Fig. 3h; Supple-
mentary Table 2). Among 7 cells (of 10) in Ifnar-/- mice, 6 shared SNVs
(Supplementary Table 3). To compare the output of MitoSV-seq with
conventional techniques, we used cortical neuronal cultures at DIV=6
and DIV=21. The purity of the primary neuronal cultures (»93%) was
confirmed by immunofluorescence and flow cytometry (Fig. 3i and
3j, respectively). mtDNA was amplified according to the conventional
techniques and sequenced, generating »1 Gbp per sample. Two SNVs
and no SVs were detected in DIV=6 CN cultures, and 27 SNVs were
seen in the 21-day-old cultures (Fig. 3k). Notably, MitoSV-seq
detected SVs and SNVs in various regions of mtDNA with optimal
sensitivity, which was not provided by the conventional method
(Fig. 3). The SNVs in Ifnar1+/+ single DA neurons were considered to
be germline and were filtered out in Ifnar1/ animals. We also com-
pared these methods with regard to contamination by NUMTs
(Fig. 3L). We observed an approximately 20-fold decrease in NUMTs
following the MitoSV-seq approach. These findings establish MitoSV-
seq as a superior method over conventional approaches, identifying
more mutations and deletions with greater heteroplasmy, especially
from single cells. These data also emphasize the need to analyse the
entire mtDNA sequence specifically in age-related disorders, rather
than merely focusing on the major arc or D-loop.
3.4. MitoSV-seq applications
A Validation of MitoSV-seq in breast cancer cell lines
We validated the MitoSV-seq method by examining the underly-
ing mtDNA mutations in breast cancer. We used two breast cancer
cell lines—MCF7, a tumourigenic cell line, and the nontumourigenic
epithelial line MCF10A—to determine the function of mtDNA instabil-
ity in human diseases in single cells (30 single cells, purified from
each line, Fig. 4a) and bulk samples (2.5 million cells from each line).
Fig. 3. Evaluation of MitoSV-seq method in dopaminergic neurons from a Parkinson disease model, Ifnar1/ mice. (a) Position of the deletion in the PC. (b) Confirmation of
4.3-kb deletion in the PC. kb, kilobase pair; WT, wild-type. (c) Single DA neuron isolation by FACS. DA, dopaminergic. (d) qPCR using TH primers confirms sorting of DA neurons. TH,
tyrosine hydroxylase. (e) RCA of mtDNA from single DA neurons amplifies concatemers that can be separated by enzymatic digestion. (f) Numerical proportions of detected varia-
tions in Ifnar1/ using MitoSV-seq. Pie chart represents total number of SVs and SNVs. (g) Heteroplasmy% distribution for individual SVs detected in Ifnar1/ mice. DEL: deletion;
INV: inversion; INS: insertion; TD: tandem duplication. (h) Position of SVs and SNVs detected with MitoSV-seq in Ifnar1/ mice. Circos plots of mouse mtDNA genome displaying
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heavy and light origins of replication (OH and LO, respectively), major arc, and D-loop (outer blue circle). mtDNA genes are displayed in the middle circle (grey lines). Depicted are
SVs as arches with deletions (blue), tandem duplications (red), inversions (green), and insertions (orange). Thickness of the arches corresponds to SV heteroplasmy. SNVs are
marked with short red lines (_). Intensity of red lines corresponds to SNV heteroplasmy. (i) Immunostaining of CN cultures showing their purity. Scale bars equal 10 microns. (j)
Flow cytometric analysis, showing 93.6% purity of CN cultures. (k) Comparison of conventional techniques with MitoSV-seq in Ifnar1/mice. Each dot represents one variation dis-
tributed according to heteroplasmy%. CNs: cortical neurons; D6: DIV=6; D21: DIV=21; W6: 6-week-old brains. (l) Number of reads aligned to the whole mouse reference genome
(mm10) obtained from MitoSV-seq and conventional methods. Total number of representative reads from both techniques (app. 3.5 million matching mouse DNA) and the rest of
the read not shown in this graph were mapped to mouse mtDNA.
Fig. 4. Validation of MitoSV-seq in breast cancer cell lines. (a) Single-cell isolation from MCF10A and MCF7 cell lines. Cell were stained with LIVE/DEAD Fixable Violet, and single
living cells were sorted. (b) Evaluation of MitoSV-seq in bulk vs single cells.
Biological samples were used in triplicate. B: bulk; SC: single cell. (c) Schematic of distribution of human mtDNA detected in bulk and single cells by MitoSV-seq. Total numbers
of detected variations in each condition and their overlapping variations are depicted in the Venn diagrams in the middle. Circos plots of human mtDNA genome displaying heavy
and light origins of replication (OH and LO, respectively), major arc, and D-loop (outer blue circle). mtDNA genes are displayed in the middle circle (grey lines). Shown are SVs as
arches with deletions (blue), tandem duplications (red), inversions (green), and insertions (orange). Thickness of the arches corresponds to SV heteroplasmy. SNVs are marked with
short red lines (_) according to their positions in mouse mtDNA. Intensity of red lines corresponds to SNV heteroplasmy. (d) Mild oxidative stress with H2O2 in MCF10A and MCF7
cell lines introduces SVs and SNVs in mtDNA. T: treated. (e) Comparison of conventional technique with MitoSV-seq to identify SVs in bulk sample. C, conventional technique; N,
new (MitoSV-seq).
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inducing agent, as a positive condition and thus validated the capac-
ity of MitoSV-seq to study mtDNA integrity.
MitoSV-seq detected more variations in single cells compared
with bulk samples for each line. We did not identify any SVs or
SNVs in bulk or individual MCF10A cells, as expected (Fig. 4b).
More SVs and SNVs were detected in single MCF7 cells (108 var-
iations in total) compared with bulk MCF7 populations (19)
(Fig. 4c). The distribution of variations in single versus bulk cells
is shown in Fig. 4c. In single-cell sequencing, SVs were observed
only in the major arc. No variations were common between sin-
gle and bulk cells. Notably, in only single-cell sequencing did we
find the previously reported rs193302991 for familial breast can-
cer (OMIM:114480).
One possible technical explanation for the lack of common
variations is that we collected 2.5 million cells for bulk sequenc-
ing and 30 single cells per line; thus, using bulk samples will
reduce the efficiency of the technique due to there being more
copies of mtDNA that need to be amplified and sequenced. Conse-
quently, bulk sequencing dilutes the number of detectable varia-
tions, whereas single-cell sequencing detects variations more
precisely. Biologically, this dispersion in variations might be
attributed to the random mutagenic effect of oxidative stress in
damaged mitochondria. Mild oxidative stress treatment effected
more damage in MCF10A and MCF7 cells, indicating the direct
mutagenic effects of ROS on mtDNA (Fig. 4d). These data confirm
the contribution of ROS to mtDNA damage and demonstrate the
impressive ability of MitoSV-seq to identify structural variations
in mtDNA.
The MitoSV-seq method (N/New) was also compared with con-
ventional techniques (C) using bulk samples, because mtDNA from a
single cell is insufficient for amplification using the two pairs of site-
specific primers that are required in the conventional methods. Total
DNA from »2.5 million cells was extracted from each biological repli-
cate, amplified using site-specific primers, and prepared for sequenc-
ing. Notably, MitoSV-seq identified more variations in bulk samples
(9 SVs) than conventional techniques (4 SVs), with 1 SV overlapping
between methods (Fig. 4e).
B Validation of MitoSV-seq in colon cancer cell lines
To confirm the broader application of MitoSV-seq, we compared
the colon cancer cell line SW480 with SW620, a colon cancer cell line
that has been isolated from a metastatic site. Ten single living cells
from each replicate were prepared for sequencing (Fig. 5a). Single-
cell and bulk sequencing was performed using MitoSV-seq.
We found more variations in single SW480 cells compared
with the bulk samples (Fig. 5b). More SVs and SNVs were also
noted at the single-cell level in SW620 cells. However, the level
of heteroplasmy of the variations was nearly the same as in the
bulk sequencing, perhaps due to the nature of SW620 cells, which
have more copies of mtDNA (»2 times more) compared with
SW480 cells [69], which will dilute the result. Overall, we found
117 variations in single SW620 cells (10 single cells per replicate)
and 13 variations in bulk SW620 cells (»2.5 million cells per
replicate), with no overlap. MitoSV-seq detected larger SVs even
in single cells: 2 large TDs (8.7 kb and 7.1 kb) were seen
using MitoSV-seq in single SW620 cells (Fig. 5c). In addition to
identifying novel variations only in single SW620 cells, MitoSV-
seq detected 2 reported variations for colorectal cancer,
COSM6716769 [70] and COSM6716773 [71] (Supplementary Table
8-11). Further, mild oxidative stress resulted in a higher load of
mtDNA damage in SW480 and SW620 cells (Fig. 5d). Compared
with conventional techniques, the same variations were detected
in SW480 cells, but MitoSV-seq identified more SVs in the SW620
line (Fig. 5e).C Validation of MitoSV-seq in peripheral blood mononuclear
cells from healthy donors and AML patients
PBMCs were isolated from four healthy donors and cultured with or
without oxidative stress, and mtDNA was prepared and sequenced by
MitoSV-seq. We characterized 15 SVs in untreated PBMCs and 19 SVs
after treatment (Fig. 6a). Although 15 mutations were detected in
healthy PBMCs, their mean heteroplasmy was »8%; thus, they might
not be deleterious. In support of our findings, low-frequency, poten-
tially high-pathogenicity mtDNA mutations have been reported in
healthy humans [72]. At low frequencies, these harmful mtDNA muta-
tions are benign, but at higher frequency, they are likely to cause mito-
chondrial dysfunction. Further, mild H2O2 treatment increased the
number of SVs to 19, with a mean heteroplasmy of»13% (Fig. 6b).
Ten single CD11b-positive myeloid cells were then sorted from
AML patients and healthy donors (in total, 30 single cells for each
condition) (Fig. 6c). For bulk sequencing, 200,000 myeloid cells were
sorted. By single-cell sequencing, more SVs and SNVs appeared in
healthy myeloid cells and AML patients (Fig. 6d). Bulk sequencing of
AML myeloid cells by MitoSV-seq generated 229 variations, whereas
at the single-cell level, 231 variations were observed, with no overlap
(Fig. 6e; Supplementary Tables 14-17). At the single-cell level, we
identified SVs in the major arc and throughout the D-loop and other
regions of mtDNA (Fig. 6e).
MitoSV-seq of bulk samples detected 9 SVs in AML, whereas the
conventional method identified 6 SVs, 3 of which were shared
between techniques (Fig. 6f).
D Validation of MitoSV-seq in MDS
Thirty single CD11b-positive myeloid cells were sorted from MDS
patients and healthy donors (Fig. 7a), and 200,000 myeloid cells were
sorted from each individual for bulk sequencing. By MitoSV-seq,
more variations were detected in single MDS cells (254 variations)
compared with the bulk samples (143), 2 of which were shared
(Fig. 7b and 7c; Supplementary Table 18-21). More variations were
also noted in single myeloid cells from healthy individuals (Fig. 7b).
Although the distribution of SVs and SNVs at the single-cell and bulk
levels was similar in MDS patients, single-cell sequencing provided
better resolution of the variations. At the single-cell level, in addition
to our novel variations, we identified 2 SNVs that have been reported
in haematopoietic and lymphoid tissue tumours: COSM56566133
and COSM5656134 [73]. Using conventional techniques for bulk MDS
samples, we identified 2 SVs, compared with 34 SVs by MitoSV-seq
(Fig. 7d).
3.5. Extended somatic mtDNA mutations are associated with tumour
progression
Based on our results, MitoSV-seq provided a universal map of the
mtDNA genome in four human malignancies at the single-cell level.
By multiple comparison of the tumours, several mutations were
shared between groups of cancers; AML and MDS had the most varia-
tions in common (9) (Fig. 8a). Notably, genomic variations were seen
in metabolism-related genes for all four malignancies (Fig. 8b), and a
specific SV was shared by all four cancers, NADH dehydrogenase 5
(MT-ND5), indicating the importance of its function and likely its dis-
ruption in cancers. Supporting our findings, 65% of somatic truncating
mutations have been reported to occur in NADH dehydrogenase 5
(MT-ND5) in colon adenocarcinoma, rectal adenocarcinoma, acute
myeloid leukaemia, ovarian serous carcinoma, and cystadenocarci-
noma [74].
The patterns of mtDNA damage in single AML and MDS cells were
similar, although in the latter, the damage expanded to more regions
(Fig. 8c). This finding is consistent with the nature of these myeloid
lineage cancers—ie, on average, 30% of patients with MDS develop
Fig. 5. Validation of MitoSV-seq in colon cancer cell lines. (a) Single living cell isolation from SW480 and SW620 cell lines. (b) Evaluation of MitoSV-seq in bulk cells vs single cells
in SW480 and SW620 cell lines. B: bulk; SC: single cell. (c) Distribution of variations in bulk and single SW620 cells with MitoSV-seq. Venn diagram represents total number of
detected variations in each condition and their overlap. Circos plots of human mtDNA genome displaying heavy and light origins of replication (OH and LO, respectively), major arc,
and D-loop (outer blue circle). mtDNA genes are displayed in the middle circle (grey lines). Also shown are SVs as arches with deletions (blue), tandem duplications (red), inversions
(green, and insertions (orange). Thickness of the arches corresponds to SV heteroplasmy. SNVs are marked with short red lines (_) according to their positions in mouse mtDNA.
Intensity of red lines corresponds to SNV heteroplasmy. (d) Identification of SVs and SNVs on treatment of SW480 and SW620 cell lines after mild oxidative stress induction. T:
treated. (e) Comparison of conventional technique with MitoSV-seq in bulk sample. C, conventional technique; N, new (MitoSV-seq).
E. Jaberi et al. / EBioMedicine 57 (2020) 102868 11from AML during disease progression [75,76]. Of the eight overlap-
ping variations that we found between AML and MDS, seven had
slightly higher heteroplasmy in MDS, whereas the m.3524C>G muta-
tion reached 100% heteroplasmy in AML patients (Fig. 8d). Using our
novel MitoSV-seq method, these data expand the evidence that
mtDNA damage that is related to defective metabolism is associated
with tumour progression.
4. Discussion
Examining mutations that are associated with mitochondrial dis-
orders remains a challenge due to phenotypic variability, genetic het-
erogeneity, and technical limitations .[9,26,27,29-31,77,78] Theprecise identification of all mtDNA mutations in mitochondrial disor-
ders is essential to understand the clinical variability, proper diagno-
sis, and prevention of many diseases [79]. Somatic mutations
accumulate in mtDNA with age and are hypothesised to function in
age-related neurodegenerative diseases, such as PD, but large
increases in mtDNA mutations have not been seen in PD [49].
One limitation of studies on PD-associated mtDNA mutations is
that due to the nature of the test, most of them have been performed
on postmortem patient brains and thus at a late stage of the disease
[28,77,78]. At this time, dopaminergic neurons in the substantia nigra
that have accumulated high levels of mutations have most likely
undergone cell death and are thus absent from the analysis. Although
it is not feasible in patients, neurons can be accessed from the brain
Fig. 6. Validation of MitoSV-seq in healthy donors and AML patients. (a) Effect of mild oxidative stress on mtDNA genetic variations in blood samples. MtDNA variations were
identified in bulk cells using MitoSV-seq. (b) Heteroplasmy rates of detected SVs in PBMCs without and with treatment. (c) Single myeloid cell isolation. AML, acute myeloid leukae-
mia. (d) Comparison of MitoSV-seq efficiency on bulk and single cells. B: bulk; SC: single cell. (e) Distribution of variations in bulk and single myeloid cells with MitoSV-seq. Venn
diagram represents total number of detected variations in each condition and their overlap. Circos plots of human mtDNA genome displaying heavy and light origins of replication
(OH and LO, respectively), major arc, and D-loop (outer blue circle). mtDNA genes are displayed in the middle circle (grey lines). Also shown are SVs as arches with deletions (blue),
tandem duplications (red), inversions (green), and insertions (orange). Thickness of the arches corresponds to SV heteroplasmy. SNVs are marked with short red lines (_) according
to their positions in mouse mtDNA. Intensity of red lines corresponds to SNV heteroplasmy. (f) Performance of conventional and the newly developed technique in myeloid cells
healthy donors and AML patients. C, conventional technique; N, new (MitoSV-seq).
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Fig. 7. Validation of MitoSV-seq in MDS patients. (a) Single myeloid cell isolation. MDS, myelodysplastic syndrome. (b) Evaluation of MitoSV-seq method in bulk and single mye-
loid cells from MDS patients. B, bulk; SC, single cell. (c) Allocation of variations detected by MitoSV-seq in bulk and single myeloid cells fromMDS patients. Venn diagram represents
total number of detected variations in each condition and their overlap, showing two detected variations at both levels. Circos plots of human mtDNA genome displaying heavy and
light origins of replication (OH and LO, respectively), major arc, and D-loop (outer blue circle). mtDNA genes are displayed in the middle circle (grey lines). Also shown are SVs as
arches with deletions (blue), tandem duplications (red), inversions (green), and insertions (orange). Thickness of the arches corresponds to SV heteroplasmy. SNVs are marked with
short red lines (_) according to their positions in mouse mtDNA. Intensity of red lines corresponds to SNV heteroplasmy. (d) Comparison of MitoSV-seq with conventional techni-
ques in bulk malignant myeloid cells fromMDS patients. C, conventional technique; N, new (MitoSV-seq).
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mouse model of PD, Ifnar1/, to purify DA neurons, allowing us to
better understand the impact of mtDNA alterations during early pro-
gression of the disease.
Mitochondrial dysfunction and the subsequent alterations in oxi-
dative phosphorylation have also been hypothesized to be involved
in tumourigenesis [80]. According to the Warburg hypothesis, cancer
originates from a non-neoplastic cell that adopts anaerobic metabo-
lism to survive after injury to its respiratory system, prompting a
model in which tumours are initiated by constant damage to mito-
chondria [14]. In support of this model, somatic mtDNA mutations
have been increasingly observed in human cancers, although theirnature and diagnostic and therapeutic implications are poorly under-
stood [21].
One major obstacle in the diagnosis of mitochondrial diseases is
the variability of the symptoms, perhaps caused by the heteroplasmy
of mtDNA damage, meaning that different versions of the mitochon-
drial genome can coexist in each cell, disrupting many cellular func-
tions. Each cell contains thousands of copies of mtDNA; thus, the
proportion of mutants in any one cell changes over time [42,81]. Hav-
ing several copies of mtDNA allows each mitochondrion to function
normally, even when some copies are mutated, allowing cells to carry
high loads of mutant mitochondrial DNA before their function is
affected. Consequently, disease symptoms emerge only when the
Fig. 8. Universal mtDNA genome comparison of four malignancies at single-cell level. (a) Spectrum of overlapping mutations in four tumours. Venn diagram depicts common
variations in multiple comparisons of four types of tumours. Common variations and their relative genes are shown under various conditions. The most common variations exist
between AML and MDS. (b) Alignment of all SVs found in the four malignancies. SVs are shown as arches (MCF7, red; SW620, green; AML, pink; MDS, blue). The only shared dam-
aged mtDNA region in all of the tumours is highlighted. (c) Distribution of variations in AML and MDS single myeloid cells, showing nearly the same pattern of mtDNA damage. SVs
are shown as arches with AML SVs in pink and MDS SVs in blue. (d) Segregation of eight common mutations in AML and MDS patients according to their heteroplasmy%.
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for certain cell types, such as postmitotic neurons, which depend
highly on mitochondria due to their high-energy metabolism [83]
and lack the capacity to proliferate, as a means of mitigating the dam-
age that accumulates. Determining the proportion of mutations in
mtDNA at the single-cell level will allow us to increase our under-
standing of mitochondrial diseases.
There are many mtDNA sequencing methods, but they are insuffi-
ciently sensitive and specific to detect mtDNA SVs and their relative
heteroplasmy, because the signal that is generated by low-hetero-
plasmy variations cannot be distinguished easily from background
noise, even with the latest NGS technology [84]. Although we
observed mutation hotspots in tissues and species, there were few
common mutations between cells within replicates, indicating that itis not possible to assess high levels of heteroplasmy in postmitotic
neurons that harbour damaged mitochondria or in various cancers by
bulk sequencing analysis. The development and application of
MitoSV-seq helped us identify mtDNA variations in single neurons
from an animal model of PD and single malignant human cells in
solid and fluid tissues. This new method has the potential to be
applied to a broad range of diseases, cell and tissue types, samples,
and species in the study of mtDNA mutations and dysfunction.
Another significant advantage of MitoSV-seq is that it requires few
cells, using as low as 10 single cells from a biological sample to gener-
ate a comprehensive profile of mtDNA variations.
With this approach, we found an unexpectedly high frequency of
heteroplasmic mtDNA variations in 70% of single DA neurons. In all
four tumours that we studied, we observed more variations at the
E. Jaberi et al. / EBioMedicine 57 (2020) 102868 15single-cell level, demonstrating the relevance of somatic mutational
heterogeneity in oncology and the superiority of single-cell over bulk
sequencing. Notably, although MitoSV-seq produces high-resolution
data even with a limited number of cells, this technique has the
potential for upscaling into a high-throughput platform. Single-cell
MitoSV-seq provides higher coverage of circular mtDNA, because all
of the reads are from mtDNA copies of a single cell, as shown in other
studies [85]. This greater coverage could thus also prevent relevant
mtDNA variations from being masked, due to other variations pre-
dominating in a smaller proportion of cells when using bulk cells or
total tissue.
Nevertheless, MitoSV-seq can be applied to bulk cells, providing
greater coverage of mtDNA mutations compared with conventional
methods. In this study, we confirmed that FACS is an efficient and fea-
sible technique for characterising dopaminergic and other neurons,
various brain cell types, and malignant myeloid cells. FACS has
advantages in purifying specific cells, based on single or multiple
cell-specific markers, over previously recommended techniques for
isolating single neurons, including MACS [48] and LCM [9,49],
because both are prone to nonspecific contamination [50]. Moreover,
RCA favours the amplification of circular templates. Using RHs in our
method effected uniform amplification of circular mtDNA, regardless
of sequence changes due to SVs and point mutations in a specific
region of mtDNA. MitoSV-seq is sequence-agnostic and can be used
to sequence mtDNA from human, mouse, and other organisms,
because circular mtDNA can be amplified using RHs rather than site-
specific primers. The PC that we have developed is a major advantage
in the quality control of the MitoSV-seq method and can be applied
to validate other mtDNA sequencing methods. The RCA approach
that is implemented in MitoSV-seq is easy to set up in a high-
throughput manner compared with classical PCR amplification, pro-
viding greater coverage of single-cell mtDNA amplification and
sequencing and being universally applicable to a variety of biological
samples, such as tissue and bulk cell extracts.
Notably, using the MitoSV-seq method specifically with our
designed PC enabled us to scan the entire mtDNA, yielding many SV
types, including deletions, inversions, short insertions, and tandem
duplications. MitoSV-seq identified many mtDNA mutations that
were otherwise unidentifiable using conventional methods and
linked them to the potential mitochondrial basis of DA neuronal
death in a PD model. The broad applicability of MitoSV-seq was con-
firmed in various cancers, expanding the evidence for altered metab-
olism as a critical hallmark of colon, breast, and haematopoietic
cancers (AML and MDS), supporting defective oxidative phosphoryla-
tion in tumourigenesis.
Our comparison of defective mtDNA regions in these tumours
highlighted MT-ND5 (NADH dehydrogenase 5) as a genetic hotspot for
mutations in cancers. NADH dehydrogenase 5 is a mitochondrial respi-
ratory complex I subunit and the largest and most complicated compo-
nent of the respiratory chain [86]. In cancer cells, defective complex I
potentiates tumour formation, resistance to cell death stimuli, and
metastasis by increasing ROS levels [87]. Further, mutations inMT-ND5
have been linked to MDS [88], AML [89], colon adenocarcinoma [74],
and breast cancer [90]. The accumulation of mutations in MT-ND5 has
been suggested to inhibit oxidative phosphorylation, causing the mal-
function of mitochondria and thus conferring selective growth advan-
tages early in oncogenesis [87], also implicating the clinical use of MT-
ND5mutations as tumour biomarkers.
MitoSV-seq could significantly improve the identification of dis-
ease-associated mitochondrial DNA mutations, the lack of which has
impeded research in this field [9,26,27,29-31,77,78], and increase our
understanding of the differences in mitochondrial biology in a cell-
specific manner. MitoSV-seq has the potential to assist in examining
the mtDNA damage that is associated with cancer cell ontology, pro-
gression, and metastatic changes in increasing numbers of purified
single cells. MitoSV-seq has widespread applicability in mtDNAsequencing, including in disease studies, conservation genetics, and
forensic identification, in which mtDNA sequence data are often
gathered. Our newly developed MitoSV-seq method for single cells
has significantly greater sensitivity and high-throughput capacity
compared with previous approaches, and its broad use might encour-
age its application in the identification of cancer-relevant mtDNA
mutations and mtDNA that are associated with metastasis and as a
high-throughput platform to examine the potential and outcomes of
cancer therapies.
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